Navigation Links
Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Date:9/4/2007

ients have had a maximum Grade 1 QTc interval prolongation, and 7 patients a maximum Grade 2; the increases were clinically asymptomatic and not associated with AEs or dose reduction or delay. One patient who experienced an event of asymptomatic Grade 3 QTc interval prolongation had ineligible baseline QTc values (Grade 2) and was withdrawn from the study. A total of 16 serious AEs were reported in 8 patients. 5 events in 4 patients were considered possibly or probably related to study drug: Grade 3 GI hemorrhage and duodenal ulcer in 1 patient, and Grade 3 pneumonia, Grade 4 pulmonary embolism, and Grade 2 haemoptysis.

About XL647

XL647 is a potent inhibitor of receptor tyrosine kinases (RTKs) that are implicated in driving tumor proliferation and vascularization (blood vessel formation). XL647 inhibits EGFR, HER2 and VEGFR2. The compound has been optimized for high potency and oral bioavailability (using in vivo systems), demonstrates excellent activity in target-specific cellular functional assays and has shown sustained inhibition of target RTKs preclinically in vivo following a single oral dose. Two phase 2 trials in patients with NSCLC are ongoing.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at <
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... (PRWEB) May 23, 2013 Can economic ... from work motivate members of the public to increase ... including Johns Hopkins Carey Business School Assistant ... yes. Pointing to a large body of recent research ... the May 24, 2013, issue of Science that the ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 The ... encourage all types of inventions. They focus on learning ... noticing this community gravitate toward bringing their ideas to ... DIY Biology Movement, works on making projects using biology. ... DNA of plants to make them glow with bioluminescence ...
(Date:5/23/2013)... Pa. , May 23, 2013 ... research and advisory firms for specialized biopharmaceutical issues, ... hepatologists, and infectious disease specialists reported that in ... patients (e.g., intentionally delaying treatment) in anticipation of ... than six months ago, when only 6 percent ...
(Date:5/23/2013)... , May 23, 2013 Pressure BioSciences, Inc. ... the Company will host a teleconference to discuss its ... business update. The teleconference information is provided below: ... Eastern Daylight Time (EDT) Dial-in: (800) 875-3456 ... 607-2001 (Int,l) Passcode: VS22823 For those unable ...
Breaking Biology Technology:Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2
... 2 Accera, Inc., a biotechnology ... (CNS) diseases, today launched Axona(TM) in the United ... first-in-class medical food for the clinical dietary management ... Dispensed by prescription, it targets the metabolic deficiencies ...
... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI ... new Senior Secured Term Loan and Revolving Credit Facility. ... agent and lender for both the Term Loan and ... draw secured term loan facility of up to $10 ...
... Inc.,(Nasdaq: BNVI ) today announced the online ... Menerba(TM) (formerly MF101) is,well tolerated, safe and effective for ... associated with menopause. , The ... safety and,efficacy of two doses of Menerba versus placebo. ...
Cached Biology Technology:Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 2Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 3Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 4Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 2Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 3Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 4Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM) 2Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM) 3Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM) 4
(Date:5/24/2013)... the immune system to combat metastatic cancer , ... destruction by the immune system. Stimulation of the immune ... are many factors that cause the immune system to ... that function to suppress the immune system response. In ... , researchers led by Ronald Levy at Stanford University ...
(Date:5/24/2013)... microRNAs (miRNAs) and other non-coding RNAs are small ... proteins. In recent years they have emerged as ... establish tissue origin for cancers of unknown primary ... for disease, but clinically tractable, diagnostic methods for ... currently available. In this issue of the ...
(Date:5/24/2013)... medication against Alzheimer,s disease, scientists have focused among other ... (A-beta). After all, it is the accumulation of A-beta that ... Starting point for the formation of A-beta is APP. Alessia ... unravel the function of APPL the fruit-fly version of ... , Alessia Soldano (VIB/KU Leuven): "We have discovered that APPL ...
Breaking Biology News(10 mins):JCI early table of contents for May 24, 2013 2JCI early table of contents for May 24, 2013 3JCI early table of contents for May 24, 2013 4JCI early table of contents for May 24, 2013 5JCI early table of contents for May 24, 2013 6JCI early table of contents for May 24, 2013 7JCI early table of contents for May 24, 2013 8A new strategy required in the search for Alzheimer's drugs? 2
... and scientific experts propose a global framework for the ... including further clinical testing In Australia. The South-Pacific ... anxiety but is restricted in some countries. Leading ... of Melbourne, Australia; Professor Rolf Teschke from Wolfgang Goethe-University, ...
... have made a significant discovery about the nature of ... Tanner, BDS, Ph.D., identified a new pathogen connected to ... wiggsiae , was present in the mouths of children ... such as Streptococcus mutans were not detected. ...
... especially for the excellence of its peacekeepers and ice ... to help countries elsewhere brace for drought, flood and ... year horizon. Within a single generation, recent studies ... by an estimated 40%, with one-third of humanity having ...
Cached Biology News:Experts propose global guidelines for safe use of Kava and new Australian study 2Forsyth team gains new insight on childhood dental disease 2Canada's role grows amid looming world water shortages in some places, more flooding in others 2Canada's role grows amid looming world water shortages in some places, more flooding in others 3Canada's role grows amid looming world water shortages in some places, more flooding in others 4Canada's role grows amid looming world water shortages in some places, more flooding in others 5Canada's role grows amid looming world water shortages in some places, more flooding in others 6Canada's role grows amid looming world water shortages in some places, more flooding in others 7
Lipid Phosphate Phosphohydrolase 2...
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
ANTI-HUMAN CYTOKINES, GROWTH FACTORS (polyclonal rabbit (or goat) antibodies) Human TARC - Biotin...
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Biology Products: